Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FH-006 vs Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma
NCT07790380Phase 3Recruiting
- Sponsor
- Hengrui
- Start
- Oct 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of FH-006 in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Hengrui. Primary endpoint: Overall Survival at 2 years. Started Oct 2026; status: recruiting.
02
Drugs
FH-006
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07790380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07790380.